drugset / Trial / NCT03113825
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Phase 2
Completed
92 enrolled
Avelas Biosciences, Inc.
Clinipace Worldwide · collabRRD International, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.
Timeline
- Start
- 2017-07-05
- Primary completion
- 2020-04-08
- Completion
- 2020-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGLOPRASTIDE | Diagnostic / imaging agent | — | Intravenous |